Market Movers (8-K)
NASDAQ
Kailera Therapeutics reported strong Q2 2026 progress, advancing its ribupatide injection and oral programs, with cash runway extending into mid-2028.
Insider Trading (Form 4)
NASDAQ
Kathleen Tregoning, Chief Corporate Affairs Officer at Kailera Therapeutics, Inc., has exercised stock options for 175,000 shares of common stock.
Schedule 13G - Passive Investments
NASDAQ
CPP Investment Board and its subsidiary, CPP Investment Board Private Holdings (4) Inc., have reported beneficial ownership of 7,304,688 shares, representing 5.6% of Kailera Therapeutics, Inc.'s common stock.
NASDAQ
RTW Investments, LP and Roderick Wong, M.D. have jointly filed a Schedule 13G, reporting beneficial ownership of 8.3% of Kailera Therapeutics, Inc. common stock as of June 30, 2026.
NASDAQ
Jiangsu Hengrui Pharmaceuticals Co., Ltd. has reported a beneficial ownership of 8.9% in Kailera Therapeutics, Inc., acquiring 11,511,853 shares.